MA53102B1 - Formulations de thiosulfate de sodium anhydre - Google Patents

Formulations de thiosulfate de sodium anhydre

Info

Publication number
MA53102B1
MA53102B1 MA53102A MA53102A MA53102B1 MA 53102 B1 MA53102 B1 MA 53102B1 MA 53102 A MA53102 A MA 53102A MA 53102 A MA53102 A MA 53102A MA 53102 B1 MA53102 B1 MA 53102B1
Authority
MA
Morocco
Prior art keywords
anhydrous sodium
sodium thiosulfate
formulations
methods
ototoxicity
Prior art date
Application number
MA53102A
Other languages
English (en)
Other versions
MA53102A (fr
Inventor
Alexander Smith
Original Assignee
Fennec Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69060534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53102(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fennec Pharmaceuticals, Inc. filed Critical Fennec Pharmaceuticals, Inc.
Publication of MA53102A publication Critical patent/MA53102A/fr
Publication of MA53102B1 publication Critical patent/MA53102B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/64—Thiosulfates; Dithionites; Polythionates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

L'invention concerne du thiosulfate de sodium anhydre, des procédés de synthèse de thiosulfate de sodium anhydre, des compositions pharmaceutiques associées, et des méthodes de traitement de l'ototoxicité. Le thiosulfate de sodium anhydre est synthétisé à partir de sulfite de sodium, de soufre et de chlorure de cétylpyridinium. Le thiosulfate de sodium anhydre est formulé en une composition pharmaceutique comprenant une solution tampon et un solvant. Ces compositions sont utiles pour éliminer ou réduire l'ototoxicité chez des patients pédiatriques recevant des agents chimiothérapeutiques à base de platine.
MA53102A 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre MA53102B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862693502P 2018-07-03 2018-07-03
US201862693503P 2018-07-03 2018-07-03
PCT/US2019/040052 WO2020009954A1 (fr) 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre
EP19830950.2A EP3817751B1 (fr) 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre

Publications (2)

Publication Number Publication Date
MA53102A MA53102A (fr) 2022-05-11
MA53102B1 true MA53102B1 (fr) 2025-11-28

Family

ID=69060534

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053101A MA53101A (fr) 2018-07-03 2019-07-01 Thiosulfate de sodium anhydre et formulations de celui-ci
MA53102A MA53102B1 (fr) 2018-07-03 2019-07-01 Formulations de thiosulfate de sodium anhydre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053101A MA53101A (fr) 2018-07-03 2019-07-01 Thiosulfate de sodium anhydre et formulations de celui-ci

Country Status (26)

Country Link
US (17) US20200023003A1 (fr)
EP (4) EP4591939A3 (fr)
JP (3) JP7561325B2 (fr)
KR (3) KR102869116B1 (fr)
CN (2) CN112805014A (fr)
AU (3) AU2019299216A1 (fr)
BR (2) BR112021000022A2 (fr)
CA (1) CA3103982A1 (fr)
DK (1) DK3817751T3 (fr)
ES (1) ES3036164T3 (fr)
FI (1) FI3817751T3 (fr)
HR (1) HRP20250792T1 (fr)
HU (1) HUE073108T2 (fr)
IL (2) IL279857A (fr)
LT (1) LT3817751T (fr)
MA (2) MA53101A (fr)
MD (1) MD3817751T2 (fr)
MX (4) MX2020013733A (fr)
MY (1) MY207630A (fr)
PL (1) PL3817751T3 (fr)
PT (1) PT3817751T (fr)
RS (1) RS67043B1 (fr)
SG (2) SG11202013199UA (fr)
SI (1) SI3817751T1 (fr)
SM (1) SMT202500266T1 (fr)
WO (2) WO2020009954A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102860981B1 (ko) 2018-02-09 2025-09-18 데시벨 테라퓨틱스, 인크. 항-백금 화학보호제를 함유하는 고장성 약제학적 조성물
RS67043B1 (sr) 2018-07-03 2025-08-29 Fennec Pharmaceuticals Inc Formulacije anhidrovanog natrijum tiosulfata
WO2020163225A1 (fr) * 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anticorps anti-cd228 et conjugués anticorps-médicament
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
US12454476B1 (en) * 2020-12-23 2025-10-28 Swamp Fox Innovations, LLC Shelf-stable dechlorinating solutions for water and related methods for use and making thereof
EP4383335B1 (fr) 2021-08-06 2026-05-20 Lg Electronics Inc Dispositif d'affichage
CN114848597A (zh) * 2022-07-11 2022-08-05 北京中科利华医药研究院有限公司 一种双室袋包装的硫代硫酸钠注射液和应用
CN116062708B (zh) * 2022-12-02 2024-09-17 东南大学 一种硫代硫酸钠的合成方法
US20240277758A1 (en) * 2022-12-28 2024-08-22 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Use of sodium thiosulfate for the treatment of sulfur mustard exposure

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191512599A (en) * 1915-09-02 1916-09-04 Thomas William Staine Hutchins Improvements in the Process for the Manufacture of Sodium Thiosulphate.
US2635980A (en) * 1950-02-11 1953-04-21 Wm S Merrell Co Stabilized sulfa drug
GB713559A (en) * 1951-12-14 1954-08-11 Kodak Ltd Improvements in the manufacture of the thiosulphates and seleno-sulphates of the alkali metals, calcium and ammonium
US2763531A (en) * 1952-11-29 1956-09-18 Eastman Kodak Co Manufacture of sodium thiosulphate from sodium sulfite and sulfur in presence of cationic surface active organic bromides
DE2851037C2 (de) * 1978-11-25 1980-10-02 Dr. Franz Koehler Chemie, 6146 Alsbach Verfahren zur Stabilisierung von für medizinische Zwecke bestimmten Natriumthiosulfat-Lösungen
JPS595387B2 (ja) * 1981-09-29 1984-02-04 トヨタ自動車株式会社 減圧鋳造装置
US4778519A (en) 1987-02-24 1988-10-18 Batric Pesic Recovery of precious metals from a thiourea leach
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
IL152433A0 (en) * 2000-04-26 2003-05-29 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
ES2615484T3 (es) 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
JP2007521315A (ja) * 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
US20070059382A1 (en) 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
WO2008058395A1 (fr) * 2006-11-15 2008-05-22 The University Of British Columbia Polymorphismes prédictifs de l'ototoxicité induite par un complexe de coordination du platine
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20110104257A1 (en) * 2008-04-10 2011-05-05 Hayden Michael R Polymorphisms predictive of platinum-coordinating compound-induced ototoxicity
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ｃｃｒ２에 대한 항체
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
ES2655883T5 (es) 2009-07-08 2022-04-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composiciones farmacéuticas que contienen tiosulfato de sodio
US20130189218A1 (en) 2011-12-23 2013-07-25 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
JP2015516407A (ja) 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
JP5478680B2 (ja) 2012-08-23 2014-04-23 小林製薬株式会社 水溶性高分子増粘剤を含有する組成物の安定化剤
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN105555902A (zh) 2013-09-16 2016-05-04 巴斯夫酶有限责任公司 受控分解酶制剂
US20160243221A1 (en) 2013-10-18 2016-08-25 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015085318A2 (fr) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Vaccins adaptatifs ciblés
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
CN103922292A (zh) * 2014-04-29 2014-07-16 辽宁石化职业技术学院 硫代硫酸钠的制备方法
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
EP3356356B1 (fr) 2015-10-01 2021-05-26 Firmenich Incorporated Composés utiles en tant que modulateurs de trpm8
EP3368054A4 (fr) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Expression régulable au moyen d'un virus adéno-associé (vaa)
AU2016344138B2 (en) 2015-10-30 2019-06-06 Pipeline Therapeutics, Inc. Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
US20170087199A1 (en) 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US20160376263A1 (en) 2016-07-26 2016-12-29 Senomyx, Inc. Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof
CN107963614A (zh) * 2016-10-20 2018-04-27 王亚玲 一种快速制备高纯度硫代硫酸钠晶体的方法
CN106379867A (zh) * 2016-10-21 2017-02-08 金川集团股份有限公司 一种生产五水硫代硫酸钠的方法
AU2018231072B2 (en) 2017-03-08 2024-04-04 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
AU2018279074B2 (en) 2017-06-08 2023-12-14 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
US10596190B2 (en) 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
KR102860981B1 (ko) * 2018-02-09 2025-09-18 데시벨 테라퓨틱스, 인크. 항-백금 화학보호제를 함유하는 고장성 약제학적 조성물
EP3810146A4 (fr) * 2018-04-25 2022-08-17 Otonomy, Inc. Formulations otiques pour l'ototoxicité induite par un médicament
RS67043B1 (sr) 2018-07-03 2025-08-29 Fennec Pharmaceuticals Inc Formulacije anhidrovanog natrijum tiosulfata
US10813947B1 (en) * 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Also Published As

Publication number Publication date
CA3103982A1 (fr) 2020-01-09
US20210015923A1 (en) 2021-01-21
EP3817751B1 (fr) 2025-06-18
EP4591939A3 (fr) 2025-11-05
PL3817751T3 (pl) 2025-09-08
HRP20250792T1 (hr) 2025-09-12
CN112805238A (zh) 2021-05-14
US20220323586A1 (en) 2022-10-13
KR20210027410A (ko) 2021-03-10
US20240165237A1 (en) 2024-05-23
LT3817751T (lt) 2025-08-11
AU2025204721A1 (en) 2025-07-10
US20220378915A1 (en) 2022-12-01
US11510984B2 (en) 2022-11-29
US11992530B2 (en) 2024-05-28
BR112021000022A2 (pt) 2021-03-30
SG11202013220SA (en) 2021-01-28
KR20250151582A (ko) 2025-10-21
US11291728B2 (en) 2022-04-05
DK3817751T3 (da) 2025-08-18
US20200009255A1 (en) 2020-01-09
US20240216511A1 (en) 2024-07-04
FI3817751T3 (fi) 2025-07-28
JP2021530420A (ja) 2021-11-11
US20230201349A1 (en) 2023-06-29
EP3818010A4 (fr) 2022-08-17
BR112021000021A2 (pt) 2021-03-30
PT3817751T (pt) 2025-07-25
JP2021530462A (ja) 2021-11-11
JP2024170538A (ja) 2024-12-10
KR102869116B1 (ko) 2025-10-14
KR20210027409A (ko) 2021-03-10
US11964018B2 (en) 2024-04-23
US10792363B2 (en) 2020-10-06
MX2020013734A (es) 2021-05-27
MY207630A (en) 2025-03-06
US20240350637A1 (en) 2024-10-24
US20240042036A1 (en) 2024-02-08
MX2025003905A (es) 2025-05-02
IL279856A (en) 2021-03-01
US20230094886A1 (en) 2023-03-30
US20230201351A1 (en) 2023-06-29
AU2019299216A1 (en) 2021-01-07
WO2020009953A1 (fr) 2020-01-09
US20230094842A1 (en) 2023-03-30
US20220160875A1 (en) 2022-05-26
SMT202500266T1 (it) 2025-09-12
US12311026B2 (en) 2025-05-27
HUE073108T2 (hu) 2026-01-28
EP4578506A2 (fr) 2025-07-02
RS67043B1 (sr) 2025-08-29
JP7561325B2 (ja) 2024-10-04
EP3817751A1 (fr) 2021-05-12
MA53101A (fr) 2021-05-12
US11617793B2 (en) 2023-04-04
CN112805014A (zh) 2021-05-14
US20230201350A1 (en) 2023-06-29
EP4578506A3 (fr) 2025-08-20
EP3818010A1 (fr) 2021-05-12
AU2019299217B2 (en) 2025-04-03
MX2024003783A (es) 2024-04-10
IL279857A (en) 2021-03-01
CA3103986A1 (fr) 2020-01-09
EP4591939A2 (fr) 2025-07-30
US20250345435A1 (en) 2025-11-13
KR102893827B1 (ko) 2025-12-03
SG11202013199UA (en) 2021-01-28
EP3817751A4 (fr) 2022-05-11
MA53102A (fr) 2022-05-11
AU2019299217A1 (en) 2021-01-14
US20230158145A1 (en) 2023-05-25
ES3036164T3 (en) 2025-09-15
MX2020013733A (es) 2021-05-27
WO2020009954A1 (fr) 2020-01-09
US20200023003A1 (en) 2020-01-23
SI3817751T1 (sl) 2025-09-30
MD3817751T2 (ro) 2025-10-31
US11998604B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
EP4591939A3 (fr) Formulations de thiosulfate de sodium
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA51530B1 (fr) Composés cycliques fondus
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA30343B1 (fr) Composition immunogene
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
MA35422B1 (fr) Imidazopyridazines amino-substituees
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
TNSN01091A1 (fr) Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MA40225A (fr) Composés dihydroisoquinolinone substitués
EP1689713A4 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
MA29239B1 (fr) Derives de n- (heteroaryl) -1h-ind0le-2-carb0xamids et leur utilisation comme ligands du recepteur vanilloide trpv1
MA32108B1 (fr) Derives d'indazole
MA52946B1 (fr) Composés
TNSN99111A1 (fr) Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson